The Remember Me feature is an automatic login process which creates a cookie on the hard drive of your computer containing a unique identifier which ASCO.org will utilize to remember you by, thereby avoiding the need to enter username and password upon subsequent visits to ASCO.org. DO NOT select this option if you share this computer with others since transactional, personal, or member only information will be accessible by other users.

To activate the Remember Me option, click the empty check box when signing in to the site. The Remember Me functionality is deactivated at the logout.

For additional information please review our Privacy Policy.

Acupuncture for pain and dysfunction after neck dissection: preliminary results of a randomized controlled trial.

Print

Sub-category:
Head and Neck Cancer

Category:
Head and Neck Cancer

Meeting:
2008 ASCO Annual Meeting

Abstract No:
6016

Citation:
J Clin Oncol 26: 2008 (May 20 suppl; abstr 6016)

Author(s):
D. Pfister, A. Vickers, G. Deng, J. S. Lee, D. Garrity, N. Lee, D. Kraus, A. Shaha, J. Shah, B. R. Cassileth

Abstract:

Background: Standard treatments for pain/dysfunction after neck dissection (ND) for cancer often have disappointing efficacy. Acupuncture (AC) has demonstrated benefits in randomized trials for treating chronic musculoskeletal pain, including in the neck and shoulder. Uncontrolled trials suggest AC to be of potential benefit for xerostomia relief. Methods: Eligible patients (pts) were >3 months post ND and radiation; had pain/dysfunction [Constant-Murley (CM) score <70] attributed to ND. Pts were randomized to weekly AC versus usual care (eg, physical therapy, analgesia, and/or anti-inflammatory drugs, per patient preference/physician recommendation) for 4 weeks. To address both efficacy and reproducibility, standard and optional AC points were used. The primary endpoint was pain/dysfunction as measured by CM score (0-100, higher is better). The secondary endpoint of xerostomia relief was measured by the Xerostomia Inventory (XI, normalized to a 0-100 scale, lower is better). Results: 70 pts were randomized to either AC (n=34) or control (n=36). Median age: 59 years; female/male: 26/44; modified radical ND: 83%; squamous cell carcinoma: 60%. Endpoint data were incomplete in 12 pts, the most common reason being failure to complete their final assessment (6 of 12 pts, 3 on each arm). Mean baseline CM scores (AC: 41.9 versus usual care: 45.0) improved more in the AC group (difference between groups 11.0; 95% Confidence Interval (CI) 2.9, 19.2; p=0.009). More pts responded to treatment (33% or more improvement in CM score) in the AC group (39% versus 7%, p=0.004). AC produced greater improvement in reported xerostomia (difference in XI 5.8; 95% CI 0.9, 10.7; p=0.021), a benefit that persisted even when the analysis was limited to pts with high baseline scores. Conclusion: Significant reductions in pain, dysfunction, and xerostomia were observed in pts receiving AC versus usual care. Although further study is needed, these data support the potential role of AC in addressing post-ND pain and dysfunction, as well as xerostomia. (Supported by CA098792).


Abstract Disclosures

Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy and are designated with a caret symbol (^) here and in the print version.


  Associated Presentation(s):

    

1. Acupuncture for pain and dysfunction after neck dissection: preliminary results of a randomized controlled trial.

Meeting: 2008 ASCO Annual Meeting
Presenter: David Pfister, MD
Session: Head and Neck Cancer (Poster Discussion)


  Other Abstracts in this Sub-Category:

    

1. A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM).

Meeting: 2008 ASCO Annual Meeting   Abstract No: 2010b   First Author: T. F. Cloughesy
Category: Head and Neck Cancer

    

2. Concomitant chemoradiotherapy (CT/RT) vs neoadjuvant chemotherapy with docetaxel/cispaltin/5-fluorouracil (TPF) followed by CT/RT in locally advanced head and neck cancer. Final results of a phase II randomized study.

Meeting: 2008 ASCO Annual Meeting   Abstract No: 6000   First Author: A. Paccagnella
Category: Head and Neck Cancer

    

3. Cetuximab added to docetaxel, cisplatin, 5-fluorouracil Induction chemotherapy (C-TPF) in patients with newly diagnosed locally advanced head and neck cancer: A phase I study.

Meeting: 2008 ASCO Annual Meeting   Abstract No: 6001   First Author: R. B. Tishler
Category: Head and Neck Cancer

    

More...


  Abstracts by D. Pfister :

    

1. Comparison of cisplatin (CDDP) and radiation (RT) to cetuximab (C) and RT for locally advanced head and neck cancer (LAHNC): A preliminary analysis.

Meeting: 2009 ASCO Annual Meeting   Abstract No: 6042   First Author: L. Koutcher
Category: Head and Neck Cancer

    

2. Prognostic risk factors to predict final pathohistology in patients undergoing radical salvage prostatectomy for locally recurrent prostate cancer after radiation therapy.

Meeting: 2009 Genitourinary Cancers Symposium   Abstract No: 142   First Author: A. Heidenreich
Category: Genitourinary Cancers - Early/Localized disease, Locally Advanced/Recurrent/Advanced disease, and Biology

    

3. Radical cystectomy in the elderly: Functional and oncological outcome.

Meeting: 2009 Genitourinary Cancers Symposium   Abstract No: 247   First Author: A. Heidenreich
Category: Genitourinary Cancers - Bladder

    

More...


  Presentations by D. Pfister :

    

1. Acupuncture for pain and dysfunction after neck dissection: preliminary results of a randomized controlled trial.

Meeting: 2008 ASCO Annual Meeting
Presenter: David Pfister, MD
Session: Head and Neck Cancer (Poster Discussion)

    

2. Discussion

Meeting: 2007 ASCO Annual Meeting
Discussant: David Pfister, MD
Session: Head and Neck Cancer (Poster Discussion)

    

3. Treatment of Radioactive Iodine-Resistant Thyroid Cancer: Current Options and Future Directions

Meeting: 2007 ASCO Annual Meeting
Speaker: David Pfister, MD
Session: Uncommon Carcinomas of the Head and Neck: Management by the Medical Oncologist (Education Session)

    

More...


  Educational Book Manuscripts by D. Pfister :

    

No items found.




 
2318 Mill Road, Suite 800, Alexandria, VA 22314   |   phone: (571) 483-1300
© 2005-2009 American Society of Clinical Oncology (ASCO).  All rights reserved worldwide.